Noble Financial analyst Robert LeBoyer reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $0.57.
According to TipRanks, LeBoyer is an analyst with an average return of -6.4% and a 27.96% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Tonix Pharma, and GeoVax Labs.
GeoVax Labs has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See the top stocks recommended by analysts >>
GOVX market cap is currently $15.05M and has a P/E ratio of -0.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.
Read More on GOVX:
- GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
- GeoVax Labs presents Gedeptin clinical data at the AACR-AHNS
- GeoVax Labs announces Gedeptin presentation at AACR-AHNS conference
- GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
- GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
